Clover Biopharmaceuticals (HKSE:02197) FCF Margin % : -775.06% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Clover Biopharmaceuticals's Free Cash Flow for the six months ended in Dec. 2023 was HK$-330.60 Mil. Clover Biopharmaceuticals's Revenue for the six months ended in Dec. 2023 was HK$42.66 Mil. Therefore, Clover Biopharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -775.06%.

As of today, Clover Biopharmaceuticals's current FCF Yield % is -153.56%.

The historical rank and industry rank for Clover Biopharmaceuticals's FCF Margin % or its related term are showing as below:

HKSE:02197' s FCF Margin % Range Over the Past 10 Years
Min: -1877.62 Med: -1877.62 Max: -1877.62
Current: -1877.62

During the past 5 years, the highest FCF Margin % of Clover Biopharmaceuticals was -1877.62%. The lowest was -1877.62%. And the median was -1877.62%.

HKSE:02197's FCF Margin % is ranked worse than
81.26% of 1046 companies
in the Biotechnology industry
Industry Median: -141.025 vs HKSE:02197: -1877.62

Clover Biopharmaceuticals FCF Margin % Historical Data

The historical data trend for Clover Biopharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals FCF Margin % Chart

Clover Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-1,877.62

Clover Biopharmaceuticals Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			-	-	-	-169,243.42	-775.06

Competitive Comparison of Clover Biopharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Clover Biopharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clover Biopharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's FCF Margin % falls into.

Clover Biopharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Clover Biopharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-806.175	/	42.936
	=	-1,877.62 %

Clover Biopharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-330.6	/	42.655
	=	-775.06 %

Clover Biopharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clover Biopharmaceuticals (HKSE:02197) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN

Website

https://www.cloverbiopharma.com

Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.

Executives

Liang Peng	2101 Beneficial owner
Liang Joshua G	2501 Other
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Aut-xxi Investment Holdings Limited	2201 Interest of corporation controlled by you
Jnry V Holdings Limited	2101 Beneficial owner
Aut-xxi Hk Holdings Limited	2101 Beneficial owner
Aut-xxi Holdings Limited	2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Super Novel International Limited	2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines